Last reviewed · How we verify

NCT07041983: SEM-TIR

24-h Energy Expenditure and Anti-obesity Medication

ENROLLING BY INVITATION Last updated 27 June 2025
What this trial tests

trial testing anti obesity medication in Obesity in 30 participants. Enrolling by invitation.

Timeline
1 July 2025
Primary endpoint
1 June 2026
1 December 2026

Quick facts

Lead sponsorUniversity of Pisa
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment30
Start date1 July 2025
Primary completion1 June 2026
Estimated completion1 December 2026

Drugs / interventions tested

Conditions studied

Sponsor

University of Pisa

Who can join

Adults 18 to 80, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

Other University of Pisa trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07041983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing